Actinium Pharmaceuticals, Inc. (ATNM)
USD 1.16
(-4.92%)
USD 1.16
(-4.92%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -51.13 Million USD | -53.06% |
| 2022 | -33.4 Million USD | -36.68% |
| 2021 | -24.44 Million USD | -11.36% |
| 2020 | -21.76 Million USD | -1.36% |
| 2019 | -21.47 Million USD | 8.94% |
| 2018 | -23.77 Million USD | 12.45% |
| 2017 | -26.85 Million USD | -1.45% |
| 2016 | -26.76 Million USD | -8.05% |
| 2015 | -24.77 Million USD | -10.4% |
| 2014 | -22.44 Million USD | -240.75% |
| 2013 | -6.58 Million USD | 17.12% |
| 2012 | -7.94 Million USD | -82549.16% |
| 2011 | 15.04 Thousand USD | 62.15% |
| 2010 | 8295.00 USD | -74.79% |
| 2009 | -14.53 Thousand USD | 44.98% |
| 2008 | -26.32 Thousand USD | -120.29% |
| 2007 | -11.99 Thousand USD | 31.6% |
| 2006 | -17.53 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -12.22 Million USD | -30.36% |
| 2024 Q1 | -9.38 Million USD | 7.52% |
| 2023 FY | - USD | -53.06% |
| 2023 Q3 | -14.15 Million USD | 8.31% |
| 2023 Q2 | -15.43 Million USD | -35.35% |
| 2023 Q1 | -11.4 Million USD | -2.44% |
| 2023 Q4 | -10.14 Million USD | 28.32% |
| 2022 Q3 | -9.57 Million USD | -24.88% |
| 2022 FY | - USD | -36.68% |
| 2022 Q1 | -5.02 Million USD | 36.46% |
| 2022 Q2 | -7.67 Million USD | -52.58% |
| 2022 Q4 | -11.13 Million USD | -16.2% |
| 2021 Q2 | -4.94 Million USD | 5.74% |
| 2021 Q4 | -7.91 Million USD | -24.86% |
| 2021 FY | - USD | -11.36% |
| 2021 Q1 | -5.24 Million USD | 16.91% |
| 2021 Q3 | -6.33 Million USD | -28.1% |
| 2020 Q3 | -5.5 Million USD | -20.82% |
| 2020 FY | - USD | -1.36% |
| 2020 Q2 | -4.55 Million USD | 18.31% |
| 2020 Q1 | -5.57 Million USD | -23.09% |
| 2020 Q4 | -6.31 Million USD | -14.78% |
| 2019 Q1 | -5.59 Million USD | 11.9% |
| 2019 FY | - USD | 8.94% |
| 2019 Q2 | -4.98 Million USD | 10.98% |
| 2019 Q3 | -6.54 Million USD | -31.41% |
| 2019 Q4 | -4.52 Million USD | 30.81% |
| 2018 Q3 | -6.18 Million USD | -26.2% |
| 2018 FY | - USD | 12.45% |
| 2018 Q1 | -6.35 Million USD | -21.3% |
| 2018 Q2 | -4.9 Million USD | 22.84% |
| 2018 Q4 | -6.35 Million USD | -2.7% |
| 2017 FY | - USD | -1.45% |
| 2017 Q4 | -5.23 Million USD | 25.8% |
| 2017 Q3 | -7.05 Million USD | 1.85% |
| 2017 Q2 | -7.18 Million USD | 7.65% |
| 2017 Q1 | -7.78 Million USD | -14.36% |
| 2016 Q4 | -6.8 Million USD | 3.87% |
| 2016 Q2 | -6.89 Million USD | -15.28% |
| 2016 Q3 | -7.08 Million USD | -2.64% |
| 2016 Q1 | -5.98 Million USD | -21.88% |
| 2016 FY | - USD | -8.05% |
| 2015 FY | - USD | -10.4% |
| 2015 Q4 | -4.9 Million USD | -6.21% |
| 2015 Q3 | -4.62 Million USD | 37.43% |
| 2015 Q2 | -7.38 Million USD | 5.94% |
| 2015 Q1 | -7.85 Million USD | -14.53% |
| 2014 Q4 | -6.85 Million USD | 2.45% |
| 2014 FY | - USD | -240.75% |
| 2014 Q1 | -4.13 Million USD | -179.0% |
| 2014 Q2 | -4.41 Million USD | -6.76% |
| 2014 Q3 | -7.03 Million USD | -59.19% |
| 2013 Q1 | -2.01 Million USD | 74.55% |
| 2013 Q2 | -1.47 Million USD | 26.91% |
| 2013 Q3 | -1.6 Million USD | -9.04% |
| 2013 Q4 | -1.48 Million USD | 7.84% |
| 2013 FY | - USD | 17.12% |
| 2012 FY | - USD | -82549.16% |
| 2012 Q1 | -7410.00 USD | -131.06% |
| 2012 Q3 | -2.39 Million USD | -185.91% |
| 2012 Q4 | -7.93 Million USD | -230.58% |
| 2012 Q2 | -839.18 Thousand USD | -11224.97% |
| 2011 FY | - USD | 62.15% |
| 2011 Q1 | -2680.00 USD | -109.78% |
| 2011 Q2 | -3361.00 USD | -25.41% |
| 2011 Q3 | -2430.00 USD | 27.7% |
| 2011 Q4 | 23.85 Thousand USD | 1081.73% |
| 2010 Q1 | -6513.00 USD | 15.5% |
| 2010 Q4 | 27.39 Thousand USD | 444.96% |
| 2010 Q3 | -7942.00 USD | 79.29% |
| 2010 FY | - USD | -74.79% |
| 2010 Q2 | -38.34 Thousand USD | -488.78% |
| 2009 Q3 | -2232.00 USD | -5.73% |
| 2009 Q1 | -3878.00 USD | 38.6% |
| 2009 FY | - USD | 44.98% |
| 2009 Q4 | -7708.00 USD | -245.34% |
| 2009 Q2 | -2111.00 USD | 45.56% |
| 2008 Q1 | -9705.00 USD | -115.67% |
| 2008 Q2 | -8304.00 USD | 14.44% |
| 2008 Q3 | -2094.00 USD | 74.78% |
| 2008 Q4 | -6316.00 USD | -201.62% |
| 2008 FY | - USD | -120.29% |
| 2007 Q3 | -4653.00 USD | -63.84% |
| 2007 Q2 | -2840.00 USD | -552.87% |
| 2007 FY | - USD | 31.6% |
| 2007 Q1 | -435.00 USD | 94.2% |
| 2007 Q4 | -4500.00 USD | 3.29% |
| 2006 Q3 | -10.03 Thousand USD | 0.0% |
| 2006 Q4 | -7504.00 USD | 25.18% |
| 2006 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | -61.405% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | -28.088% |
| Azitra, Inc. | -10.67 Million USD | -379.051% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | -525.061% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -645.087% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | -78.776% |
| CEL-SCI Corporation | -27.56 Million USD | -85.519% |
| iBio, Inc. | -14.02 Million USD | -264.667% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | -106.728% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -153.34% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | -124.009% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -268.502% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -965.208% |
| NanoViricides, Inc. | -7.75 Million USD | -559.138% |
| Oragenics, Inc. | -20.87 Million USD | -144.905% |
| BiomX Inc. | -22.81 Million USD | -124.107% |
| BiomX Inc. | -22.81 Million USD | -124.107% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 538.846% |
| Palatin Technologies, Inc. | -29.03 Million USD | -76.121% |
| Scorpius Holdings, Inc. | -35.08 Million USD | -45.742% |